Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies

Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies

Conditions: Solid Tumor, Adult; Triple Negative Breast Cancer; Colorectal Cancer; Hepatocellular Carcinoma; Osteosarcoma; Epithelial Ovarian Cancer; Gastric Cancer; Non-small Cell Lung Cancer; Malignant Melanoma
Interventions: Biological: CRX100 suspension for infusion; Combination Product: Fludarabine; Combination Product: Cyclophosphamide
Sponsors: BioEclipse Therapeutics
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

February 1, 2024Comments OffClinicalTrials.gov | Endocrinology Clinical Trials | Endocrinology Studies | US National Library of Medicine
Comments